Do You Need a License to Sell Peptides in District of Columbia?

Almost certainly you need something — but rarely the single permit most operators picture. Selling anything as a business in the District of Columbia generally involves basic commercial registration, and that is a completely separate question from whether a drug-distribution or pharmacy license applies to your inventory, which is separate again from whether research-use-only (RUO) materials belong in that regulated lane at all. Three questions, three different regulators, three different sets of consequences. This article is informational and is not legal advice — the only person who can tell you what your specific model requires is a licensed attorney reviewing your specific facts, alongside the relevant District regulator.

Three separate questions hiding inside one

The first question is the mundane one: does your entity need to be registered and licensed to do business at all? Nearly every jurisdiction has some form of entity registration and general business licensing regime, and it applies to businesses that sell laboratory supplies exactly as it applies to businesses that sell office chairs. This is usually the least ambiguous part of the analysis and the part your accountant or formation attorney can resolve quickly.

The second question is the one that actually keeps people up at night: does what you are handling fall into a regulated drug-distribution category, triggering wholesale distributor licensure, facility requirements, or pharmacy oversight? The honest answer is that this turns on facts specific to your operation — what the material is, how it is labeled, whether you take physical possession, whether you are shipping across jurisdictional lines, and, critically, what your marketing says the material is for. Nobody can answer that from a blog post, and any supplier who tells you confidently that no license is required is telling you something they are not qualified to say.

The third question is the lane question. Research-use-only materials are not FDA-approved drugs, are not sold for human consumption, and are supplied to businesses and laboratories for laboratory research. Whether your intended activity keeps you inside that lane, or quietly moves you out of it, is a legal determination — not a labeling one. Which brings us to the mechanism that trips up most new resellers.

What moves a business out of the research lane

In practice, it is rarely the molecule that changes a company's regulatory posture. It is the claims. Intended use is generally inferred from how a product is described, labeled, packaged, and sold — the storefront copy, the product page, the email sequence, the answer a sales rep gives on the phone. A vial described as a laboratory reference material and a vial described in terms of what it will do for a person are, from a regulatory standpoint, potentially very different products even when the contents are identical.

That is the mechanism worth internalizing before you build a catalog. The compliance work is not a one-time filing; it is an ongoing discipline over everything your business publishes. Practically, that discipline tends to include:

• Labeling and copy that keeps research-use framing intact everywhere, including social posts, ad creative, and any downstream marketplace listing.
• No bundling of administration supplies with compounds in a way that implies a ready-to-use kit for a person. Suppliers and resellers who pair vials with injection supplies are making an implicit claim about intended use, whatever the disclaimer at the bottom of the page says.
• Batch-level documentation retention, so that for any unit you sold you can produce the certificate of analysis that corresponds to that exact lot.
• Customer representations — what your buyers are told, in writing, about permitted use.

Whether those practices are sufficient in your case is your counsel's call. What is not in dispute is that they are the raw material your counsel will need to work with.

The questions to take to your attorney and the District regulator

Walk into the conversation with a structured list rather than a general worry. It shortens the engagement and produces a usable answer. Do not treat a competitor's website, a forum thread, or a supplier's reassurance as legal cover — none of those parties bears the consequence if the analysis is wrong.

Expect hedged answers on some of these, and treat confident absolutes with suspicion. Regulatory posture in this category has been unsettled and can shift; the durable move is to build an operation whose documentation would survive scrutiny under the stricter reading, rather than one that depends on the looser reading holding.

How supplier qualification works from the other side of the transaction

A legitimate wholesale supplier runs its own screen on you, and that screen is a useful diagnostic. A supplier that will open a bulk account for anyone with a credit card is telling you something about how it handles risk generally — including the risk you inherit when their product reaches your customers.

The Real Peptides Wholesale Partner Program uses a three-step application. You submit your business information, that information is reviewed and verified, and once approved you are assigned to a pricing tier and can order. The verification step exists precisely because the supplier's exposure and the buyer's exposure are linked. It is friction, and it is the right kind of friction.

What that screen does not do is resolve your licensing position. No supplier can license you, and none can indemnify you into compliance. What a supplier can do is make sure that when a regulator, a payment processor, or a large downstream account asks you to substantiate what you sold, you can answer with documents instead of adjectives.

What to verify before the first purchase order

Sourcing due diligence in this category is mostly about whether claims are checkable. Three patterns are worth screening for.

Testing you cannot verify. Plenty of suppliers advertise purity figures. Fewer will show you the underlying analysis, and fewer still will let you match a certificate of analysis to the specific batch number printed on the vial you received. That batch-to-COA match is the whole point — a generic COA for a compound, unlinked to a lot, proves nothing about the unit in your hand. Ask how HPLC purity is determined, what else the batch panel covers beyond purity, and whether analysis is performed by an independent laboratory.

Documentation sold as an upsell. Some operations treat COAs as a paid add-on or release them only on request to serious buyers. Testing documentation is the product's quality evidence; charging for it inverts the relationship between the supplier and the buyer's ability to do diligence.

Pricing you can only get by asking. Opaque tier structures, quotes that vary by who is asking, and minimums disclosed only after you have handed over contact details all make it impossible to model a catalog. You cannot plan inventory around a number you have to negotiate every time. Margins and volume economics in this category vary widely by category and order size, and any supplier quoting you a guaranteed profitability figure is guessing on your behalf.

Add to that list the boring operational questions: where does fulfillment originate, what is the realistic shipping window, how are damaged or short shipments handled, and what happens when a batch fails internal review.

What Real Peptides does differently

Real Peptides supplies research-use-only peptides to businesses through its Wholesale Partner Program, and the program is built around evidence a buyer can check independently rather than claims a buyer has to accept.

Compounds are produced to 99%+ HPLC purity. Every batch runs through a multi-panel testing protocol rather than a single purity check, so the analysis covers more than one dimension of product quality. Certificates of analysis are publicly verifiable — a prospective partner can review lab results before opening an account, not after, and can match documentation to batches rather than taking a summary figure on faith. Fulfillment is US-based, with orders shipping in 5–7 days, which matters when you are managing shelf coverage rather than one-off purchases. Onboarding runs through the three-step application described above: submit, verify, order at your assigned tier.

Catalog breadth is part of the calculation too. Businesses building a research-use catalog can plan around established categories such as the popular peptides collection rather than assembling inventory from several suppliers with inconsistent documentation standards. One note on scope, because it comes up in nearly every wholesale conversation: Real Peptides does not offer semaglutide, tirzepatide, retatrutide, or melanotan wholesale. If a supplier is offering those to you casually, that is information about the supplier.

Everything supplied is for laboratory research use only and is not for human consumption. How you structure your own business around that framing is a matter for your attorney.

Where a qualified buyer goes from here

The sequence that works is short. Get your entity and general business registration in order. Take the table above to a regulatory attorney and get a written read on whether distribution licensure is in scope for your specific model. Fix your copy and labeling before you have volume, not after. Then qualify a supplier on documentation you can verify yourself. If those pieces are in place and you are ready to build a research-use catalog on a transparent tier structure with batch-matched COAs behind it, the Wholesale Partner Program application is the next step.

For more on how the program is structured, see the wholesale peptides program overview, read the broader guidance on do you need a license to sell peptides, or apply for a wholesale account to begin verification.